Carbazochrome sodium sulfonate (AC-17) is an antihemorrhagic for use in the treatment of hemorrhoids

97%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

Soluble in DMSO > 10 mM

Carbazochrome (0.1–1 M) reverses the barrier dysfunction induced by tryptase, thrombin and bradykinin without affecting the endothelial permeability enhanced by Ca(2+) ionophores such as ionomycin and A23187 or phorbol 12-myristate 13-acetate. Carbazochrome reverses the tryptase-induced formation of actin stress fibres and disruption of VE-cadherin in the monolayers of cultured porcine aortic endothelial cells (PAECs). Carbazochrome (0.1-10 M) reduces concentration-dependently the enhancement of inositol triphosphate formation from myo-inositol induced by bradykinin and thrombin. Carbazochrome significantly blocks the hyperpermeability induced in cultured bovine endothelial cells by tryptase, thrombin and proteinase-activated receptor-2 agonist peptide (SLIGKV-NH(2)). Carbazochrome significantly decreases the t-PA:Ag in the culture medium of human umbilical vein endothelial cells (HUVEC), while it has no significant effect on the PAI-1:Ag.

Carbazochrome (10 mg/kg) reverses the ioxaglate-induced vascular hyperpermeability in a dose-dependent manner in rats. Carbazochrome (10 mg/kg) significantly inhibits the decrease in arterial pO(2).